Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hung-Chih Yang

Showing results (141-150 of 144) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 144 results.
Gut|April 22, 2014
Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trialChen-Hua Liu, Chun-Jen Liu, Chung-Feng Huang, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|November 2, 2024
Addition of neutrophil-to-lymphocyte ratio to Pre-DAA FIB-4 does not increase prediction value for de novo liver complications in hepatitis CChun-Ming Hong, Tung-Hung Su, Shih-Jer Hsu, et al.
Scientific Reports|June 18, 2017
Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C PatientsMei-Hsuan Lee, Chung-Feng Huang, Hsueh-Chou Lai, et al.
Hepatology Communications|October 29, 2024
Clinical care guidance in patients with diabetes and metabolic dysfunction-associated steatotic liver disease: A joint consensusJee-Fu Huang, Tien-Jyun Chang, Ming-Lun Yeh, et al.
Pageof 15

Showing results (141-150 of 144) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 144 results.
Gut|April 22, 2014
Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trialChen-Hua Liu, Chun-Jen Liu, Chung-Feng Huang, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|November 2, 2024
Addition of neutrophil-to-lymphocyte ratio to Pre-DAA FIB-4 does not increase prediction value for de novo liver complications in hepatitis CChun-Ming Hong, Tung-Hung Su, Shih-Jer Hsu, et al.
Scientific Reports|June 18, 2017
Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C PatientsMei-Hsuan Lee, Chung-Feng Huang, Hsueh-Chou Lai, et al.
Hepatology Communications|October 29, 2024
Clinical care guidance in patients with diabetes and metabolic dysfunction-associated steatotic liver disease: A joint consensusJee-Fu Huang, Tien-Jyun Chang, Ming-Lun Yeh, et al.
Pageof 15